The board of directors at its meeting to be held on May 13, 2016, will consider raising funds through various options, the company said in a BSE filing.
The options include issuance of equity shares, convertible bonds, debentures through qualified institutional placement (QIP), GDR, ADR for an aggregate amount of up to Rs 10,000 crore.
Moreover, the board will also consider raising up to Rs 3,500 crore in the 2016-17 fiscal by issuing secured/unsecured redeemable non-convertible debentures on a private placement basis.
Headquartered in Ahmedabad, Zydus Cadila group has global operations in four continents spread across the US, Europe, Latin America and South Africa and 25 other emerging markets.
The group's operations cover healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.